摘要 目的：探讨恩替卡韦治疗失代偿期乙肝肝硬化的临床疗效。方法：选择失代偿期乙肝肝硬化患者共38例，随机分为治疗组20例，对照组18例。两组均给予还原型谷胱甘肽、甘草酸苷等综合保肝治疗。对照组加用拉米夫定100mg,口服，1/d及阿德福韦脂10mg,口服，1/d。治疗组加用恩替卡韦 0.5mg,口服，1/d。结果：两组在HBV-DNA定量水平下降、肝功能改善、凝血酶原活动度及Child-Pugh积分等方面与治疗前比较,有统计学意义;而两组间比较无统计学意义。 结论: 恩替卡韦这里失代偿期乙肝肝硬化,疗效明确,安全性较好。

关键词：恩替卡韦;拉米夫定;乙肝;失代偿期;乙肝肝硬化。

Entecavir therapy in patients with decompensated HBV-related cirrhosis

Su Li Wen

464 hospital of People Liberation Army (Tian jin,300381)

Abstract -ive To evaluate the effect of entecavir on patients with decompensated hepatitis B virus (HBV)-related cirrhosis. Methods A total of 38 cases of decompensated HBV-related cirrhosis were randomly divided into treatment group(n=20)and a control group (n=18). -d on a comprensive liver-preventing treatment regimen, including reduced glutathione, diammonium glycyrrhizinate in both group, the patients in the treatment group were treated with entecavir (0.5mg,1/d),while those in the control were lamivudine (100mg,1/d) and adefovir (10mg,1/d) for 52 weeks. Results viral load ,liver function, serum fibrosis indexes, thrombingen activity and Child-Pugh score improved significantly compared with those before antiviral treatment (P0.05). Conclusion Entecavir is effective and safe for patients with decompensated HBV-related cirrhosis.

Key words entecavir lamivudine chronic hepatitis B decompensation hepatitis B virus (HBV)-related cirrhosis.